Novel AMP-activated protein kinase activators and their potential for mitigating renal injury and fibrosis

Geoff Harley1, Peter F Mount2

  • 1Department of Nephrology (Kidney Laboratory), Austin Health, Melbourne, Victoria, Australia.

Insights

Novel AMP-activated protein kinase (AMPK) activators show promise for treating kidney disease by improving energy regulation. These new therapies offer potential protection against kidney injury and fibrosis, though clinical application faces challenges.

Area of Science:

  • Biochemistry
  • Nephrology
  • Pharmacology

Background:

  • Kidney injury and fibrosis are linked to disordered cellular energy metabolism.
  • AMP-activated protein kinase (AMPK) regulates energy metabolism and is protective in kidney injury models.
  • Traditional AMPK activators have limitations due to indirect action and off-target effects.

Purpose of the Study:

  • To review mechanisms of kidney injury and fibrosis.
  • To outline the current landscape of novel AMPK activators.
  • To discuss experimental evidence and potential of novel AMPK activators in kidney protection.

Main Methods:

  • Review of existing literature on kidney injury, fibrosis, and AMPK activators.
  • Analysis of experimental data on novel AMPK activator mechanisms.
  • Discussion of preclinical findings and clinical development challenges.

Main Results:

  • Dysregulated energy metabolism is a key target for kidney disease treatment.
  • Novel AMPK activators demonstrate protective mechanisms against kidney injury and fibrosis in preclinical studies.
  • Existing evidence supports AMPK activators as a promising therapeutic strategy for kidney health.

Conclusions:

  • Novel AMPK activators represent a promising therapeutic avenue for kidney injury and fibrosis.
  • Further research is needed to address challenges such as cardiac hypertrophy, oncogenesis, and pharmacokinetics for clinical translation.
  • Despite challenges, significant preclinical data motivates continued development of novel AMPK activators for kidney disease.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
909
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
255
Acute Kidney Injury V: Interprofessional Care01:20

Acute Kidney Injury V: Interprofessional Care

Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
290
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.3K
Acute Kidney Injury II: Pathophysiology01:29

Acute Kidney Injury II: Pathophysiology

Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
869
Acute Kidney Injury I: Introduction01:22

Acute Kidney Injury I: Introduction

Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...
554